Dyskusja nad zastosowaniem przeciwnaczyniowej terapii podtrzymujacej u chorych na rozsianego raka jelita grubego – opis przypadku
Abstract
Author(s): Krzysztof Adamowicz, Marzena Welnicka-Jaskiewicz
Colorectal cancer is the second most common cause of cancer deaths worldwide. Although progress in the development of new drugs over the last two decades have expanded treatment options for this disease, many significant problems relating to their optimization remains to be solved. Recent advances in molecular characteristics of colorectal cancer are building the foundations for further improvement of existing drugs and the development of new targeted therapies. Bevacizumab is a recombinant humanized monoclonal antibody that selectively binds to human vascular endothelial growth factor. The results of many studies and meta-analysis showing the efficacy of bevacizumab in the first and second line treatment are inconclusive because of the variety of subgroups of patients in studies. Furthermore, still do not have any marker response to treatment with inhibitors of the anti-VEGF agents. The results of studies using bevacizumab maintenance therapy is promising, but still ambiguous.
<Share this article
Editors List
-
Prof. Elhadi Miskeen
Obstetrics and Gynaecology Faculty of Medicine, University of Bisha, Saudi Arabia
-
Ahmed Hussien Alshewered
University of Basrah College of Medicine, Iraq
-
Sudhakar Tummala
Department of Electronics and Communication Engineering SRM University – AP, Andhra Pradesh
-
Alphonse Laya
Supervisor of Biochemistry Lab and PhD. students of Faculty of Science, Department of Chemistry and Department of Chemis
-
Fava Maria Giovanna
Onkologia i Radioterapia peer review process verified at publons
Indexed In
- Directory of Open Access Journals
- Scimago
- SCOPUS
- EBSCO A-Z
- MIAR
- Euro Pub
- Google Scholar
- Medical Project Poland
- PUBMED
- Cancer Index
- Gdansk University of Technology, Ministry Points 20